Photo: ReutersNew Delhi: Multinational stent makers pressed for differential pricing of advanced coronary stents before the national drug pricing watchdog on Monday, after a government panel rejected the demand last week. AdvaMed has suggested considering alternatives to price control such as trade margin rationalization and more scientific approaches that facilitate differential pricing for innovative medical technologies. In its report, the eight-member sub-committee that met on 25 January and considered stent makers’ arguments said there were “no grounds” to create a new category. Indian stent makers, meanwhile, continue to oppose differential pricing. Ltd said the market has grown for both Indian and global stent makers.

Source: Mint February 05, 2018 18:22 UTC